AUGMENTIN TABLET 1 g

Land: Singapore

Taal: Engels

Bron: HSA (Health Sciences Authority)

Koop het nu

Bijsluiter Bijsluiter (PIL)
18-11-2013
Productkenmerken Productkenmerken (SPC)
27-02-2024

Werkstoffen:

AMOXYCILLIN TRIHYDRATE 1004.43MG EQV AMOXYCILLIN; POTASSIUM CLAVULANATE 148.91MG EQV CLAVULANIC ACID

Beschikbaar vanaf:

GLAXOSMITHKLINE PTE LTD

ATC-code:

J01CR02

Dosering:

875 mg

farmaceutische vorm:

TABLET, FILM COATED

Samenstelling:

AMOXYCILLIN TRIHYDRATE 1004.43MG EQV AMOXYCILLIN 875 mg; POTASSIUM CLAVULANATE 148.91MG EQV CLAVULANIC ACID 125 mg

Toedieningsweg:

ORAL

Prescription-type:

Prescription Only

Geproduceerd door:

SmithKline Beecham Limited

Autorisatie-status:

ACTIVE

Autorisatie datum:

1996-10-07

Bijsluiter

                                 
 
AUGMENTIN
TM 
BD TABLETS 
AMOXICILLIN TRIHYDRATE - POTASSIUM CLAVULANATE 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
_AUGMENTIN_ 625 mg tablets: Each tablet contains 500
mg amoxicillin (as 
amoxicillin trihydrate) and 125 mg clavulanic acid
(as potassium clavulanate). 
_AUGMENTIN_ 1 g tablets: Each tablet contains 875
mg amoxicillin (as amoxicillin 
trihydrate) and 125 mg clavulanic acid
(as potassium clavulanate). 
PHARMACEUTICAL FORM 
_AUGMENTIN_ 625 mg tablets: A white to off- white oval- shaped
film-coated tablet, 
engraved with AC and a score line on one side and plain on
the other side.   
_AUGMENTIN_ 1 g tablets: A white to off- white oval- shaped
film-coated tablet, 
engraved with AC. 
 
CLINICAL PARTICULARS 
INDICATIONS 
_AUGMENTIN_ is an antibiotic agent with a notably broad
spectrum of activity against 
the commonly occurring bacterial pathogens in general practice and
hospital.  The 
β-
lactamase inhibitory action
of clavulanate extends the spectrum of amoxicillin to 
embrace a wider range of organisms,
including many resistant to other 
β-lactam 
antibiotics. 
AUGMENTIN should be used in
accordance with local official antibiotic-prescribing 
guidelines and local susceptibility data. 
_AUGMENTIN_ oral presentations for twice daily dosing,
are indicated for short-term 
treatment of bacterial infections at the following sites: 
_Upper respiratory tract infections (including ENT) _e.g.
tonsillitis, sinusitis, otitis 
media. 
_Lower respiratory tract infections _e.g. acute exacerbation
of chronic bronchitis, lobar 
and bronchopneumonia. 
_Genito-urinary tract infections _e.g. cystitis, urethritis,
pyelonephritis. 
_Skin and soft tissue infections,_ e.g. boils, abscesses,
cellulitis, wound infections. 
_Bone and joint infections_ e.g. osteomyelitis. 
_Other infections _e.g. septic abortion, puerperal sepsis,
intra-abdominal sepsi
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                AUGMENTIN
BD TABLETS
AMOXICILLIN TRIHYDRATE - POTASSIUM CLAVULANATE
QUALITATIVE AND QUANTITATIVE COMPOSITION
_AUGMENTIN_ 625 mg tablets: A white to off-white oval-shaped
film-coated tablet,
debossed with ‘AC’ and a score line on one side and plain on the
other side.
Each tablet contains 500 mg amoxicillin (as amoxicillin trihydrate)
and 125 mg
clavulanic acid (as potassium clavulanate).
_AUGMENTIN_ 1 g tablets: A white to off-white capsule-shaped
film-coated tablet,
debossed with ‘AC’ on both sides and a score line on one side.
Each tablet contains 875 mg amoxicillin (as amoxicillin trihydrate)
and 125 mg
clavulanic acid (as potassium clavulanate).
CLINICAL INFORMATION
INDICATIONS
_AUGMENTIN_ is an antibiotic agent with a notably broad-spectrum of
activity against
the commonly occurring bacterial pathogens in general practice and
hospital. The
beta-lactamase inhibitory action of clavulanate extends the spectrum
of amoxicillin to
embrace a wider range of organisms, including many resistant to other
beta-lactam
antibiotics.
_AUGMENTIN_ should be used in accordance with local official
antibiotic-prescribing
guidelines and local susceptibility data.
_AUGMENTIN_ oral presentations for twice daily dosing, are indicated
for short-term
treatment of bacterial infections at the following sites:
_Upper respiratory tract infections (including ENT) _e.g. recurrent
tonsillitis, sinusitis,
otitis media.
_Lower respiratory tract infections _e.g. acute exacerbation of
chronic bronchitis
(AECB), lobar and bronchopneumonia.
_Genito-urinary tract infections _e.g. cystitis, urethritis,
pyelonephritis.
_Skin and soft tissue infections_ e.g. boils, abscesses, cellulitis,
wound infections.
_Bone and joint infections_ e.g. osteomyelitis.
_Dental infections _e.g. dentoalveolar abscess, pericoronitis, acute
periodontitis.
_Other infections _e.g. septic abortion, puerperal sepsis,
intra-abdominal sepsis.
Susceptibility to _AUGMENTIN_ will vary with geography and time (see
_Pharmacological Properties, Pharmacodynamics_ for further
in
                                
                                Lees het volledige document
                                
                            

Bekijk de geschiedenis van documenten